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Abstract: In Sudanese traditional medicine, decoctions of the stem bark of Anogeissus leiocarpa are 
used for the treatment of tuberculosis (TB). However, this plant has not been investigated before for 
its antimycobacterial effects. Our screening results show, for the first time, that many extracts of 
various parts of A. leiocarpa exhibit growth inhibitory activity against Mycobacterium smegmatis. 
Minimum inhibitory concentration (MIC) values ranged between 625 and 5000 µg/mL, with an ethyl 
acetate extract of the root showing the lowest MIC value. The good antimycobacterial effects of the 
root part could be due to its high concentration of ellagic acid derivatives, ellagitannins, and 
flavonoids. Thin layer chromatography (TLC) fractionation resulted in some fractions with better 
activity than the starting point crude methanol extract (MIC 2500 µg/mL). Those fractions with the 
lowest MIC values contained a high number of antioxidant compounds. Fractions 3 and 4 (MIC 1500 
and 1000 µg/mL, respectively) contained high concentrations of di-methyl ellagic acid ([M-H] − 
329.0318). Fraction 6 (MIC 2000 µg/mL) contained a lower concentration of di-methyl ellagic acid and 
was not as growth inhibitory as fractions 3 and 4. Moreover, in fraction 3, an acetylated ellagic acid 
derivative ([M-H] − 343.0477) and di-methyl-ellagic acid xyloside ([M-H]− 461.0739) were tentatively 
characterized. Di-methyl ellagic acid xyloside was also present in fraction 4 and could strongly 
contribute to the antimycobacterial effect of this fraction. Additionally, protocatechuic acid ([M-H]-
at m/z 153.0196) was present in fraction 4. Our antimycobacterial results obtained from this research 
justify the use of A. leiocarpa in Sudanese folk medicine against cough related to TB. Roots, stem bark, 
and leaves of A. leiocarpa are sources for new potent anti-TB drug lead compounds.  
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1. Introduction 
Tuberculosis (TB) is an infectious disease that mostly affects the lungs, but it also affects other 
organs such as bones, kidneys, or the brain [1]. Mycobacterium tuberculosis, the main causative 
bacterium of TB, is spread through cough, talk, and/or sneeze. However, age, sex, and socio-economic 
environment (poverty), as well as immunosuppression (HIV-infection), are considered as major 
factors affecting TB prevalence [1,2]. Approximately one third of the world population is estimated 
to be infected by TB, with most infections in a latent phase [3,4], and most of the new global TB cases 
are localized in Africa [5]. In 2019, the World Health Organization (WHO) [6] declared that 484,000 
of the new global TB cases were resistant to the first-line antibiotic rifampicin, and 78% of them 
developed multidrug-resistant tuberculosis (MDR-TB). The new TB cases in 2018 were 
predominantly found among males, with a total of 5.4 million new cases, followed by 3.2 million new 
TB cases among females and 1.0 million new TB cases among children [5]. Moreover, at present, 1.0 
million children die annually from MDR-TB [3,4]. According to the WHO, the global TB situation 
needs a focused effort and emergency action, with an estimated total cost of US $3.3 billion 
dollars/year to slow down the spread of the TB and to hinder the incidence of new resistant strains 
[1]. 
In some African countries with high poverty levels, a high number of the deaths among the poor 
people result from TB [7]. This is due to the scarcity of new and advanced medical inspection 
equipment, as well as laboratories lacking diagnostic equipment, high tariffs for TB drugs (US 
$25/person), and low income levels (less than US $1 per person/day) [8]. Thus, in many African 
countries, a high number of the TB patients use traditional medicine, including plant-based medicines 
for the treatment of prolonged cough and other symptoms related to TB.  
In Africa, many plant species belonging to the family Combretaceae are used customarily against 
cough and respiratory infections, including prolonged cough [9–12]. Anogeissus leiocarpa, the African 
birch (in Sudanese: Al-Sahab بهصلا) is an example of these plants. A. leiocarpa occurs naturally in 
Central, East, and West African countries (Figure 1). According to African plant database and plant 
list database 2010 [13], there are nine species belonging to the genus Anogeissus, of which eight are 
native to tropical Asia. A. leiocarpa is the only African species, and it grows in various geographical 
zones and different vegetation types such as bushlands, savannas, and woodlands, and due to its 
good tolerance to drought and high soil salinity, it can even grow in drylands and arid and semi-arid 
grasslands [9,14,15]. A. leiocarpa is a deciduous tree that can reach heights of 15–18 m (Figure 1B). The 
bark is greyish and scaly, and the branches are drooping. The inflorescences are globose heads with 
yellow flowers, and the fruits are winged [16] (Figure 1C). In Sudanese traditional medicine, the stem 
bark is made into a decoction for the treatment of cough [17]. Additionally, there are ethno-
pharmacological reports on the specific use of A. leiocarpa against tuberculosis, including symptoms 
such as bloody and prolonged cough [18,19]. Other uses in African traditional medicine of decoctions 
and macerations of A. leiocarpa include a broad spectrum of infectious diseases such as bacterial and 
fungal infections, as well as symptoms related to these infections, such as diarrhea and skin rashes 
[18,20,21]. 
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Figure 1. (A) Occurrence of Anogeissus leiocarpus in Africa according to various vegetation mapping 
projects. (TAFP), red dots; Naturalis Herbarium specimen, yellow spots; Africa Nord project, orange 
spots; FLOTRO project, violet dots (Source: African Plant Database); (B) Anogeissus leiocarpa growing 
in semi-arid and woodland savannah zone in Sudan; (C) leaves and flowers; (D) scaly bark. Photos: 
E. Y. A. Salih and H. H. Gibreel 2006. 
Comparatively little research has been performed to verify the ethno-pharmacologically claimed 
antimicrobial effects of A. leiocarpa, and even fewer publications have dealt with the phytochemistry 
of this species (Figure 2). However, in accordance with the traditional medicinal uses of A. leiocarpa, 
some researchers have demonstrated significant in vitro antibacterial effects of its extracts against 
some bacterial strains, such as Staphylococcus aureus, Pseudomonas aeruginosa, Shigella dysenteriae, 
Escherichia coli, and Klebsiella pneumoniae (Figure 2) [18,22–25].  
 
Figure 2. Trend in the number of research papers on Anogeissus leiocarpa from 1998 to 2017. The figure 
illustrates that most of the research papers have dealt with other research aspects than antimicrobial 
or phytochemical research. Thus, there is a need for more research in the mentioned research areas. 
Source: Scopus research data base. 
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Phytochemical studies of extracts from A. leiocarpa have mainly reported on polyphenolic and 
phenolic compounds (Figure 3). Among these compound groups, we and other researchers have 
reported on the occurrence of a number of ellagitannins, ellagic acid and its derivatives, flavellagic 
acid, gallic acid and its derivatives, gallotannins, epicatechin-3-O-gallate, and epicatechin [18,26–30] 
(Figure 3). In addition, a number of flavonoids have been reported to occur in A. leiocarpa (Figure 3) 
[16,18,26,31–34].
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Figure 3. Chemical structure of ellagic acid derivatives and other chemical constituents detected earlier from A. leiocarpa: (A) dimethyl ellagic acid xylopyranoside, 
(B) dimethyl ellagic acid, (C) ellagic acid xylopyranoside, (D) epsilon-Viniferin, (E) avicularin, (F) taxifolin (dihydroquercetin), (G) methyl-taxifolin 
(dihydroisorhamnetin), (H) aromadendrin (dihydrokaempferol), (I) ampelopsin (dihydromyricetin), (J) pinocembrin, (K) guaijaverin, (L) pterostilbene, (M) 
pinosylvin (trans-dihydroxystilbene), (N) methyl pinosylvin, and (O) kynurenic acid [18,26,27]. Source for molecular structures: (CAS), 2020. 
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Till today, only one earlier study investigated the antimycobacterial effects of A. leiocarpa using 
the Bacillus Calmette-Guérin tuberculosis vaccine containing a live attenuated strain of 
Mycobacterium bovis [20]. However, to the best of our knowledge, A. leiocarpa extracts have not been 
tested before against Mycobacterium smegmatis. M. smegmatis is known to have a high genetic 
homology with M. tuberculosis, as well as being rather resistant against rifampicin, and it is thus 
considered to be a representative organism to use in antimycobacterial testing [35,36]. Therefore, in 
this current paper, we present our research that aimed to validate the African traditional medicinal 
use of water extracts (macerations) and decoctions of A. leiocarpa against tuberculosis and its 
symptoms, such as cough, using M. smegmatis as the test bacterium. This paper presents the 
antimycobacterial results of a number of extracts and fractions of various polarities from the stem 
bark, roots, and leaves of A. leiocarpa. Additionally, high performance liquid chromatography with a 
diode array detector (HPLC-DAD) and ultra-high performance liquid chromatography quadrupole 
time of flight mass spectrometry (UHPLC/QTOF-MS) were used for the phytochemical profiling of 
an antimycobacterial root extract and its preparative reversed phase 18 (RP18)-thin layer 
chromatography (TLC) fractions. Preparative RP18-TLC was used to trace the portion of the root 
extract that could be responsible for its good antimycobacterial effects.  
2. Results 
2.1. Extracts and Their Antimycobacterial Effects  
Thirty-nine extracts, four thin layer chromatography fractions, and five pure compounds known 
to occur in A. leiocarpa were tested for their growth inhibitory effects on M. smegmatis. The results are 
presented in Tables 1 and 2.  
Table 1. In vitro antimycobacterial activity against Mycobacterium smegmatis ATCC 14468 of extracts 
and fractions of various polarities from Anogeissus leiocarpa roots, stem bark, and leaves. Results 
obtained with an agar diffusion method. Activity index (AI) was calculated in relation to rifampicin. 
Extracts of Anogeissus Leiocarpa IZD SEM AI 
R. MeSox 21.33 0.33 0.45 
R. acetone 15.45 0.33 0.32 
R. hex NA   
R. EtOAc 28.50 0.29 0.60 
R. aqu 18.67 0.17 0.39 
R. Dic 16.00 0.00 0.34 
R. H2O* 18.67 0.17 0.39 
R. Me* 21.33 0.17 0.45 
R. HH2O 13.30 0.17 0.28 
Rb. acetone 18.33 0.17 0.39 
Rb. Me* 17.67 0.17 0.37 
Rb. Dic 16.33 0.17 0.34 
Rb. H2O* 18.67 0.17 0.39 
Rb. hex NA   
W. MeSox 20.17 0.33 0.42 
W. hex NA   
W. H2O* NA   
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W. CHCl3 13.67 0.17 0.29 
W. HH2O 15.00 0.00 0.32 
W. aqu 14.00 0.00 0.29 
W. EtOAc 25.17 0.17 0.53 
W. Me* 20.33 0.33 0.40 
B. EtOAc 28.67 0.17 0.60 
B. aqu 25.00 0.00 0.53 
B. MeSox 14.83 0.17 0.31 
B. hex NA   
B. CHCl3 NA   
B. H2O* 17.67 0.17 0.37 
B. Me* 18.67 0.17 0.39 
B. HH2O 20.67 0.17 0.44 
L. EtOAc 30.50 0.29 0.64 
L. aqu 24.67 0.17 0.52 
L. H2O* 26.67 0.17 0.56 
L. hex NA   
L. Me* 20.00 0.29 0.42 
L. acetone 19.94 0.29 0.42 
L. Dic NT   
L. MeSox 24.17 0.17 0.51 
L. HH2O 20.33 0.33 0.43 
Rifampicin 47.5 0.29 1.00 
Methanol NA   
Hexane NA   
W, stem wood; B, stem bark; R, root; L, leaves; Rb, root bark; Me*, cold methanol extracts; EtOAc, 
ethyl acetate extracts; hex, hexane extracts; Dic, dichloromethane; CHCl3, chloroform extracts; aqu, 
aqueous extracts; HH2O), hot water decoctions; MeSox, methanolic Soxhlet extracts; H2O*, cold water 
extracts; NA, not active; and NT, not tested; AI, activity index, which was calculated in relation to the 
antibiotic rifampicin; IZD, diameter of inhibition zones recorded in mm as the mean of triplicates (n 
= 3) ± SEM of three experiments; methanol, and hexane were used as solvent control; most promising 
results (IZD ≥ 20 mm) are indicated by bold text. Filter paper disks (⌀ 12.7 mm) were saturated with 
200 µL extracts/fractions (50 mg/mL) and rifampicin (10 mg/mL). 
Table 2. Minimum inhibitory concentration of the extracts and fractions of A. leiocarpa against 
Mycobacterium smegmatis ATCC 14468. 
A. leiocarpa Crude Extracts and Fractions 
Total 
Activity 
(in 
mL/g) 
MIC (in µg/mL) 
W. MeSox 40.2 5000 ** 
W. Me* 4.2 5000 
B. EtOAc 21.6 2500 ** 
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B. aqu 16 5000 
B. HH2O 13.6 5000 
R. MeSox and its preparative reversed phase 18 (RP18)-thin layer 
chromatography (TLC) fractions (Fr3-Fr8) 43.2 2500 
Fr 3 (Rf 0.095)  1500 (IC 89) ** 
Fr 4 (Rf 0.159)  1000 (IC 89) ** 
Fr 6 (Rf 0.276)  2000 (IC 91) ** 
Fr 8 (Rf 0.457)  3000 (IC 90) ** 
R. Me* 5.6 5000 
R. EtOAc 7.04 625 ** 
L. MeSox 101.6 5000 
L. HH2O 14.8 5000 
L. H2O* 28.4 2500 
L. EtOAc 38 2500 
Pure compounds known to be present in A. leiocarpa  
Gallic acid  500 (IC 98) ** 
Quercetin  250 (IC 94) ** 
Apigenin  250 (IC 97) ** 
Corilagin   1000 (IC 94) ** 
Ellagic acid  500 (IC 98) ** 
Rifampicin  39.06 µg/mL (3.90 µg/mL, IC 98) ** 
** Results obtained with a microplate method. Other results not marked with ** were obtained with 
an agar diffusion method. W, stem wood; B, stem bark; R, root; L, leaves; Me*, cold methanol extracts; 
EtOAc, ethyl acetate extracts; HH2O, hot water extracts or decoctions; MeSox, methanolic Soxhlet 
extracts; H2O*, cold water extracts, macerations; total activity in mL/g; IC, inhibitory concentration 
that indicates the % of growth inhibition compared to the growth control at that concentration; Fr3, 
Fr4, Fr6, and Fr8 were obtained from R. MeSox using RP18-TLC. 
An ethyl acetate extract of the roots of A. leiocarpa showed the lowest MIC value (625 µg/mL) of 
all extracts in this study and a large inhibition zone diameter (IZD) of 28.50 mm; additionally, the 
growth inhibitory effects of this extract were dose-dependent. 
Since a Soxhlet methanol extract of the roots also gave good growth inhibitory results (IZD 21.33 
mm), an attempt was made to find the antimycobacterial components or compound combinations in 
this extract using RP18-TLC fractionation (Figure 4). Accordingly, the thin-layer fractions Fr 3 (Rf 0.09), 
Fr 4 (Rf 0.15), and Fr 6 (Rf 0.27), all enriched with ellagic acid derivatives, showed better growth 
inhibition than the crude extract (MIC 2500 µg/mL), with MIC values of 1500, 1000, and 2000 µg/mL, 
respectively (Table 2). In comparison, we found that pure ellagic acid gave an MIC value of 500 
µg/mL (Table 2). The most polar TLC fraction, Fr 8 (Rf 0.45) showed a weaker antimycobacterial effect 
than the crude extract, with an MIC value of 3000 µg/mL (Table 2).  
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Figure 4. (I) RP18-TLC fractions (Fr1–Fr12) of a Soxhlet extract obtained with methanol from the root 
of A. leiocarpa. (A) Fractions at 366 nm, (B) fractions at 254 nm, and (C) fractions sprayed with the 2,2-
diphenoyl-1picrylhydrazy (DPPH) reagent, with the yellow color indicating antioxidant activity. (II) 
Thin layer chromatography fingerprints of the standard compounds corilagin (Rf 0.549), ellagic acid 
(Rf 0.173), and gallic acid (Rf 0.721) (A) at 254 nm, (B) at 366 nm, and (C) after being sprayed with the 
DPPH reagent. Fractions marked with bold font (Fr 3, Fr 4, Fr 6, and Fr 8) were obtained in sufficient 
amount for antimycobacterial testing. 
As shown in Tables 1 and 2, the hydrophilic extracts of the leaves gave good antimycobacterial 
effects in general, such that an ethyl acetate extract gave the largest IZD of 30.50 mm and an MIC of 
2500 µg/mL, followed by a cold water extract (IZD 26.67 mm and MIC 2500 µg/mL), an aqueous 
fraction (IZD 24.67 mm), a methanolic Soxhlet extract (IZD 24.17 mm), and a hot water decoction 
(IZD 20.33 mm).  
Moreover, ethyl acetate extracts of the stem bark and stem wood of A. leiocarpa showed large 
diameters of inhibition zones against the growth of M. smegmatis (IZD 28.67 and 25.17 mm, 
respectively, and an MIC value of 2500 µg/mL for the ethyl acetate fraction of the stem bark).  
In contrast to the whole root, only weak or no growth inhibition was observed for the root bark 
extracts of A. leiocarpa (Table 1).  
In contrast to the more polar extracts, less polar or non-polar extracts such as dichloromethane 
and n-hexane extracts of the various parts of A. leiocarpa mostly showed weak or no growth inhibition 
of M. smegmatis (Table 1). This result was in accordance with previous research that non-polar extracts 
of A. leiocarpa were not active against a number of strains of gram-positive bacteria [21].  
2.2. Phytochemistry and Antioxidant Effects 
We made a reversed phase 18 (RP18) TLC fractionation in order to decipher compounds or 
combinations of compounds in a methanol Soxhlet root extract of A. leiocarpa that could contribute to 
the good antimycobacterial effects of this extract. Our TLC-fractionation resulted in 12 fractions 
(Figure 4), of which four (Fr 3, Fr 4, Fr 6, and Fr 8) (Figure 4) were obtained in sufficient concentrations 
to be used for antimycobacterial testing and the phytochemical analysis. Our HPLC-DAD and 
UHPLC/QTOF-MS results of the qualitative composition of the separated TLC fractions revealed that 
the fractions Fr 3, Fr 4, and Fr 6 contained ellagic acid derivatives as their main compounds (Table 3 
and Figure 5B). The HPLC-DAD retention times, [M-H]- data, and (UVλ) absorption spectra of 
compounds characterized from the TLC fractions of the root methanol extract of A. leiocarpa are 
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shown in Table 3. Fraction 3 (Fr 3), the most non-polar part of the crude methanol root extract, 
appeared as a fluorescent blue spot on the TLC plate at 366 nm (Figure 4). Fraction 3 contained six 
compounds altogether, all ellagic acid derivatives, and three of these compounds—(18) di-methyl 
ellagic acid xyloside (C21H18O12, tR 23.47 min, [M-H]− at m/z 461.0766), (21) di-methyl-ellagic acid 
(C16H10O8, tR 28.04 min, [M-H]− at m/z 329.0318), and (24) an acetylated ellagic acid derivative (tR 
35.08, [M-H]− at m/z 343.0477)—could be characterized from this fraction (Table 3). Di-methyl ellagic 
acid was also found in fractions Fr 4 and Fr 6, and it was the main compound both in Fr 4 and Fr 3 
(Table 3 and Figure 4). Moreover, di-methyl ellagic acid xyloside was also present in Fr 4. 
Additionally, in fraction Fr 4, (2) protocatechuic acid (syn. dihydroxybenzoic acid, C7H6O4, tR 3.69 
min, [M-H]− at m/z 153.0196) was present, although it was assumed that this compound would 
mainly appear in the most polar TLC fractions (Table 3). In addition, in each TLC fraction, there were 
a number of ellagic acid derivatives, for which only the UV maxima absorption spectra from HPLC-
DAD could be obtained (Table 3).  
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Figure 5. (A) Methanolic Soxhlet extract of the root of A. leiocarpa. (1) Gallic acid, (2) protocatechuic acid, (3a) flavonoid, (3b) alkaloid, (4a) flavonoid, (4b) ellagitannin, 
(5) aromadendrin, (6) di-galloyl-β-D-glucose, (7) ampelopsin, (8) methyltaxifolin, (9a*) flavonoid, (9b) isomer of methyltaxifolin, (9c) flavonoid, (10) ellagic acid 
derivatives, (11) taxifolin, (12) ellagic acid derivatives, (13) ellagic acid derivatives, (14) ellagic acid derivative, (15) di-methyl ellagic acid glucoside, (16) 
pentagalloylglucose, (17) ellagic acid derivatives, (18) di-methyl ellagic acid xylopyranoside, (19) ellagitannin, (20) ellagitannins, (21) di-methyl ellagic acid, (22a) 
ellagitannin, (22b) ellagitannin, (23) pinosylvin, (24) acetylated ellagic acid derivative, (25) ellagic acid derivatives, and (26) methylpinosylvin. (B) TLC 
chromatograms of RP18 TLC fractions (Fr3–Fr8) obtained from the methanol Soxhlet extract (A); ** Unknown compounds; (EA der), ellagic acid derivatives; (Di-Me 
EA xyl), dimethyl ellagic acid xyloside; (ET), ellagitannin; (Ace-EA der), acetylated ellagic acid derivatives; and (PCA), protocatechuic acid. Main compounds with 
bold text. 
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Table 3. HPLC-DAD, UHPLC/QTOF-MS and RP18 TLC data of fractions obtained from a methanol Soxhlet root extract of A. leiocarpa. Some compounds numbered 
according to the HPLC-DAD chromatograms in Figure 5. 
RP18-Thin Layer 
Chromatography  
Fractions and Their 
Compounds 
Molec
ular 
Formu
la 
Rt HPLC-
DAD  
Rt LC-
MS 
[M-
H]- 
Exact 
Calculated 
MW 
UVλ max 
(HPLC-DAD) 
Peak 
Area % 
Distance Moved in cm 
on TLC plate 
RP18 TLC Rf 
Value 
DPPH 
Reactive  
Fr3 MeSox               1.2 0.0945 Yes 
Ellagic acid derivative   20.04       254, 366 2.71     
Di-methyl ellagic acid 
xyloside (18) 
C21H18
O12 23.47 9.65 
461.0
739 462.0739 246, 376 4.93 
    
Di-methyl-ellagic acid 
(21)  
C16H10
O8 28.09 11.25 
329.0
318 330.0318 246, 380 38.43 
    
Ellagic acid derivative   29.94       248, 374 8.05     
Unknown  33.06    216, 248, 374 4.31     
Acetylated ellagic acid 
derivative (24)  35.08  12.80 
 343.0
477  344.0477 222, 246, 370 5.99 
    
Fr4 MeSox               1.9 0.1496 Yes 
Protocatechuic acid (2) C7H6O
4 3.69 1.34 
153.0
196 154.0196 
218, 220, 260, 
294 1.5 
    
Ellagic acid derivative  18.12       246, 370 1.63  
Ellagic acid derivative  18.90       210, 254, 362 1.7     
Ellagic acid derivative  19.98       210, 254, 368 19.12     
Di-methyl ellagic acid 
xyloside (18) 
C21H18
O12 23.52    246, 376 9.09     
Di-methyl ellagic acid 
(21) 
C16H10
O8 28.07 11.25 
329.0
318 330.0318 246, 380 21.92 
    
Ellagic acid derivative  35.08       246, 382 3.18     
Fr6 MeSox               3.5 0.2756 Yes 
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Unknown flavonoid (9a)  14.66    232, 276, 350 2.31    
Ellagic acid derivative   17.54    254, 378 9.84    
Ellagic acid derivative  18.12    246, 370 13.41    
Unknown   18.93    254, 360 7.77    
Ellagic acid derivatives  19.99    254, 362 22.09    
ellagitannin (unknown)  23.64    220, 248, 378 2.92    
Di-methyl ellagic acid 
(21) 
C16H10
O8 29.01 11.25 
329.0
318 330.0318 248, 376 3.99    
Fr8 MeSox               5.8 0.4567 Yes 
Unknown  5.057    242 3.65    
Unknown  13.07       210, 230, 282 3.99     
Ellagic acid derivative  17.52    254, 384 3.96    
(Fr), fraction; (DMF), distance moved by fraction on the RP18-TLC plate; DPPH, 2,2-diphenoyl-1picrylhydrazyl reagent measuring antioxidant activity; and MW, 
exact calculated mass that was calculated from the molecular formula.. 
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Five unknown ellagitannins (4b), (19), (20), (22a) and (22b) were present in the crude methanol 
extract of the roots of A. leiocarpa at tR (HPLC-DAD) 8.99, 26.10, 27.68, 31.24, and 31.58 min, 
respectively (Figure 5A). These ellagitannins were not found in the TLC fractions. However, a small 
concentration of an unknown ellagitannin (HPLC-DAD peak area 2.9%) was detected in Fr 6 at tR 
23.64 min (Table 3 and Figure 5B).  
As shown in Figures 4I,II and Table 3, we made a qualitative analysis of the antioxidant 
capacity of compounds in the TLC fractions of A. leiocarpa roots by spraying TLC plates containing 
these fractions with a DPPH reagent. Our results showed that all TLC fractions contained 
compounds with good antioxidant effects, but the strongest effects were shown by fractions 3, 4, 
and 6.  
3. Discussion 
Our results demonstrated that polyphenol-rich extracts and fractions of the root, leaf. and stem 
bark of Anogeissus leiocarpa possess good antimycobacterial effects against M. smegmatis. Surprisingly, 
although there have been a number of publications dealing with the antibacterial effects and 
phytochemistry of A. leiocarpa, no research has previously been done on the antimycobacterial effects 
of A. leiocarpa extracts against M. smegmatis or M. tuberculosis. Thus, our results now prompt more 
research on antimycobacterial fractions and compounds in this plant and related species. In the 
following parts of the discussion section, we discuss the most potent extracts and fractions, the impact 
of their extraction yields and antioxidative effects on their antimycobacterial activities, and the 
compounds in these extracts and fractions that are likely to contribute to their antimycobacterial 
effects.  
3.1. Extraction Yields, Total Antimycobacterial Activity and Antioxidative Effects  
The % yield of extraction in relation to the MIC gives an important indication for the total 
antimicrobial activity of a plant extract. Eloff, 2000 [37] presented the total activity of a plant extract 
as the mass extracted from the plant material (in mg/1000 mg starting material) divided by the MIC 
value (in mg/mL) of this extract. The total activity is an indication of the volume to which 1 g of a 
plant extract can be diluted without losing its antibacterial effect, and it is expressed as mL/g. In 
respect to this, the extraction yields resulting from our extractions when using different solvents were 
taken into account for A. leiocarpa in order to estimate the total activities of the extracts (Table 2). This 
information could be important to improve the use of A. leiocarpa as traditional medicine for the 
treatment of TB. In general, our results indicated that the most polar extracts, such as methanol and 
water extracts, gave better extraction yields when compared to the non-polar solvents (Figure 6). The 
extraction yields of the decoctions and macerations of A. leiocarpa were, however, quite low in general; 
11.9% for a root bark decoction, 7.1% for a maceration of the leaves, and 4.7% for a maceration of the 
stem bark (Figure 5). Therefore, the use of water as extractant is maybe not optimal while preparing 
traditional remedies of A. leiocarpa. Our results suggested that ethanol extracts could be an option to 
macerations and decoctions to extract an optimal concentration of antimycobacterial compounds. 
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Figure 6. Percentage of extraction yield. (A) ethyl acetate (EtOAc), aqueous (aqu), and acetone (acet) in sequential extraction; (B) hot (HH2O) and cold water (H2O*) 
extraction; and (C) methanol extraction, Soxhlet extraction (Me sox), and cold methanol extraction (Me*); (A.L.), Anogeissus leiocarpa; (Rb), root bark; (R), root; (W), stem 
wood; (B), stem bark; and (L), leaf. Extracts obtained using the same solvent are marked with the same color or color–texture. 
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Moreover, in agreement with Orlando et al. [26], we found that the extraction yields 
considerably varied between different plant parts, such that Soxhlet extraction with methanol 
resulted in a low extraction yield for the roots (10.8%) compared to the stem bark (47.1%) and leaves 
(50.8%) (Figure 6). Thus, the total antimycobacterial activity for the root Soxhlet methanol extract was 
calculated to be 43.2 mL/g (108 mg extracted from 1 g plant material divided by the MIC in mg/mL, 
2.5 mg/mL). For the leaves, the total activity was 101.6 mL/g, even though the MIC value for the leaf 
Soxhlet methanol extract was as high as 5000 µg/mL. Thus, despite of the lower MIC value of the root 
methanol extract compared to the leaf methanol extract, the total activity of the leaf Soxhlet extract 
was better (Table 2). This also implies that leaf extracts in alcohol of A. leiocarpa could be good sources 
for antimycobacterial compounds, since the extraction yields with alcohol are high.  
Small extraction yields could limit the use of some extracts of A. leiocarpa (and plants in general) 
as sources of antimycobacterial compounds. Moreover, the active compounds can sometimes be 
present in very small concentrations, which could be a hinderance when trying to elucidate 
antimycobacterial compound structures [38].  
According to our qualitative DPPH-TLC assay of thin-layer chromatography fractions obtained 
from a methanol root extract of A. leiocarpa, some of the fractions, such as Fr 3, Fr 4, and Fr 6, gave 
strong antioxidative effects (Figure 4). These antioxidant effects could have positive impacts on the 
antimycobacterial effects of the mentioned TLC fractions. Our results are in accordance with previous 
research that A. leiocarpa contains a number of polyphenolic compounds with good antioxidant effects 
[32].  
3.2. Ellagic Acid Derivatives and Ellagitannins in A. Leiocarpa and Their Suggested Impact on Its 
Antimycobacterial Effects  
In our screenings, the lowest MIC value (625 µg/mL) against M. smegmatis was obtained with an 
ethyl acetate extract of the roots of A. leiocarpa. The good antimycobacterial effects of this extract could 
have been due to ellagic acid derivatives and ellagitannins in this extract. In addition, we observed 
that the antimycobacterial effects of a methanol extract of the root (MIC 2500 µg/mL) was improved 
when it was fractionated using preparative reversed phase RP18-TLC and methanol:water:acetic acid 
(50:50:1) as eluent. When compared to the crude extract, fractions 3 and 4, enriched with ellagic acid 
derivatives, gave lower MIC values of 1500 and 1000 µg/mL, respectively (Table 2). Di-methyl ellagic 
acid xyloside (Figure 3D) is especially suggested to strongly contribute to the antimycobacterial 
effects of both fractions (Figure 5 and Table 3), since di-methyl ellagic acid xyloside inhibited the 
growth of Mycobacterium intracellulare and showed an outstanding MIC value of 4.88 µg/mL against 
M. smegmatis and M. tuberculosis MTCS2 [39]. The differences in MIC values, when compared to our 
study (4.88 µg/mL versus 1000–1500 µg/mL in our study) could have been due to the fact that our 
thin layer fractions contained a small total concentration of di-methyl ellagic acid xyloside (4.9% and 
9% peak area in HPLC-DAD chromatograms, in fraction 3 and 4, respectively) and, in addition, 
contained a mixture of unknown ellagic acid derivatives. Moreover, Kuete et al. [39] used a different 
strain of M. smegmatis. Besides, di-methyl ellagic acid xyloside has also been identified from the stem 
bark of another species of Anogeissus, A. latifolia [40]. 
The xylose sugar part of di-methyl ellagic acid xyloside is thought to be important for its 
antimycobacterial activity [41], and accordingly, the aglycone di-methyl ellagic acid was found to be 
less active. In agreement with this, our screening result of ellagic acid against M. smegmatis (MIC 500 
µg/mL) showed that pure ellagic acid is not very active, and it needs to have a sugar molecule or 
other side groups attached to increase its activity. Thus, ellagic acid derivatives, and especially ellagic 
acid glycosides from Anogeissus leiocarpa (Figure 3) and related species, might have a significant value 
as scaffolds for new anti-TB drugs.  
Another ellagic acid derivative isolated from A. leiocarpa, 3,3,4′-tri-0-methyl-flavellagic acid, was 
found to inhibit the growth of S. aureus, E. coli, and P. aeruginosa [42] but was not tested for its growth 
inhibition against mycobacterial strains. Thus, Anogeissus spp. are good sources for antibacterial 
ellagic acid derivatives with antibacterial properties. 
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Though some ellagic acid derivatives have been found to give strong antimycobacterial effects, 
not much is known about their mechanisms of action on Mycobacterium spp. It has been suggested 
that ellagic acid derivatives interfere with mycobacterial cell wall synthesis [43]. In accordance with 
this suggestion, a study revealed that pteleoellagic acid had a high in silico docking score to MabA, 
a protein involved in the fatty acid elongation complex II (FAS II) system in M. tuberculosis [44]. 
Additionally, di-methyl ellagic acid xyloside inhibits arabinogalactan synthesis in the mycobacterial 
cell wall [43,44].  
A. leiocarpa roots and stem bark are rich source of ellagitannins (ET). In this investigation, we 
found that an ethyl acetate extract of A. leiocarpas roots gave the lowest MIC of 625 µg/mL against M. 
smegmatis (Table 2). The good antimycobacterial effects of this extract could partly be attributed to its 
ellagitannins. Moreover, we found that an ethyl acetate extract of the stem bark, enriched with 
ellagitannins, gave fairly good antimycobacterial activity. In our previous investigation, we 
tentatively characterized ten unknown ellagitannins in this stem bark ethyl acetate extract of A. 
leiocarpa based on HPLC-UV-DAD data (UVλ maxima and retention times) [18]. Moreover, previously 
reported ellagitannins in the stem bark and leaves of A. leiocarpa include a corilagin sanguiin H-4, 
punicalagin, castalagin (1-epi-vescalagin), casuarinin, chebulagic acid, and punicacortein (Figure 7) 
[26,31]. These mentioned ellagitannins may play a significant role for the in vitro antimycobacterial 
effect of the stem bark ethyl acetate extract of A. leiocarpa that we present in this paper. In this respect, 
we found that corilagin expressed a mild growth inhibitory effect against M. smegmatis with an MIC 
value of 1000 µg/mL (Table 2). Some other ellagitannins are also known to possess in vitro growth 
inhibitory effects against mycobacterial strains. For example, Asres et al., 2001 [45] found that 
punicalagin isolated from the stem bark of Combretum molle completely inhibited the growth of M. 
tuberculosis ATCC 27294 at a concentration of 1000 µg/mL, and Diop et al., 2019 [46] found that 
fractions enriched with the ellagitannin isomers punicalagin α and β effectively inhibited the growth 
of Mycobacterium marinum, whereas a fraction enriched with punicacortein D showed a weaker effect. 
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Figure 7. Chemical structure of ellagitannins identified from Anogeissus spp. and A. leiocarpa: (A) flavano-ellagitannin anogeissinin A, (B) anogeissinin B, (C) 
cornusiin B, (D) anogeissinin, (E) casuarinin, (F) castalagin (R1 = H; R2 = OH) and vescalagin (R1 = OH; R2 = H), (G) corilagin, and (H) isomer of corilagin sanguiin 
H4. DHHDP: dehydro-hexahydroxydiphenoyl; HHDP: hexahydroxydiphenoyl. Source for molecular structures: CAS, 2020. 
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However, ETs are mostly too large to be absorbed as such in vivo, and in the human body, they 
are mainly present as their degradation products of urolithins [47]. Thus, the role of ETs in anti-TB 
traditional remedies might mostly be due to their metabolically available products, the urolithins 
[46,48]. Since we also found that the same ellagitannins were present in a water extract of the stem 
bark of A. leiocarpa (HPLC-DAD result not published), this could justify the traditional use of water 
extracts (decoctions and macerations) of A. leiocarpa for the treatment of tuberculosis and its 
symptoms, such as (bloody and prolonged) cough, assuming that the urolithins and ellagic acid and 
its derivatives, resulting from the degradation of the ETs would be antimycobacterially active or that 
some metabolically unchanged smaller molecular ETs would be active constituents in the extract. 
Accordingly, in their investigation on antimycobacterial compounds of Combretum aculeatum, Diop et 
al., 2019 [46] suggested that the effects of the traditional decoction of this plant could mostly be due 
to ellagic acid and urolithins.  
In vitro investigations on the mechanism of action of ETs on bacteria have indicated that the 
presence of galloyl groups and the presence and number of dehydro-hexahydroxydiphenoyl ester 
(D-HHDP) and hexahydroxydiphenoyl ester groups (HHDP) in ellagitannins influence their 
antimicrobial effects [9,49,50]. 
3.3. Flavonoids in A. Leiocarpa and Their Suggested Impact on Its Antimycobacterial Effects  
Our results indicated that a methanol Soxhlet extract of the root of A. leiocarpa have 
antimycobacterial effects. Flavonoids could have partly been behind these effects, since in our 
previous investigation, we found that this extract is rich in flavonoids, such as aromadendrin (syn. 
dihydrokaempferol), ampelopsin (syn. dihydromyricetin), methyl-taxifolin (syn. 
dihydroisorhamnetin), and taxifolin (syn. dihydroquercetin) [18]. Moreover, we have now found 
some additional flavonoids in this root extract, as shown in Figure 5A, at HPLC-UV-DAD Rt 4.74, 
8.64, 14.37, and 14.38 min. The molecular masses for these flavonoids remain to be elucidated.  
Previous research has demonstrated that methanol and water extracts of the stem bark and leaf 
of Anogeissus leiocarpa are rich in flavonoids such as luteolin, apigenin, quercitrin, isorhamnetin, 
isoquercetin, quercetin-3-O-glucoside, luteolin-7-O-glucoside, kaempferol, rutin, quercetin-O-
galloylhexoside, myricetin-O-hexoside, apigenin-6-C-glucoside, reinutrin, avicularin, myricetin, 
guaijaverin, eriodictyol, narcissin, naringenin, pinocembrin, quercetin, catechin, and vitexin 
[26,32,42]. In addition the dimer, procyanidin B-2 was found to be present in an ethyl acetate extract 
of the leaves [32].  
Some flavonoids occurring in A. leiocarpa have been tested for their antimycobacterial effects. 
For example, taxifolin was found to give outstanding growth inhibitory effects against M. tuberculosis 
H37Rv with an MIC value of ≤ 12.5 µg/mL [51,52]. Thus, the taxifolin that we found in high 
concentrations in a methanolic root extract of A. leiocarpa could be an important contributor to the 
growth inhibitory effects of this extract against M. smegmatis. Additionally, isorhamnetin showed 
potent growth inhibitory effects against multi-drug and extensively drug-resistant clinical strains of 
M. tuberculosis H37 Rv [53]. Moreover, quercetin-3-O-glucoside gave an MIC of 150 µg/mL against 
M. tuberculosis H37 Rv [54]. Most of the flavonoids that have been investigated for their 
antimycobacterial effects have been found to possess moderate to weak growth inhibitory effects. For 
example, quercetin showed MIC values of 200 µg/mL against M. tuberculosis H37 Rv [55], and luteolin 
gave an MIC value of 699 µM against M. tuberculosis [56]. Thus, our results on the weak growth 
inhibitory effects of apigenin and quercetin against M. smegmatis (both flavonoids gave MIC values 
of 250 µg/mL in our test system) are in line with these previous findings.  
Many authors’ results have suggested that the (most of the) flavonoids in plant extracts 
(including extracts of A. leiocarpa) act in concert with other compounds present in the extracts, rather 
than functioning as the principal antimycobacterial compounds alone. Indeed, it has been found that 
fractions containing combinations of flavonoids, such as a fraction enriched in quercetin and 
guercitrin isolated from a Brazilian medicinal plant Scutia buxifolia (Rhamnaceae), gave promising 
growth inhibitory effects against M. smegmatis (MIC 78 µg/mL) [57]. Moreover, some flavonoids have 
been found to act synergistically with conventional antimycobacterial drugs. For example, a 
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trihydroxylated methoxychalcone isolated from Galenia africana (Aizoaceae) was found to have 
synergistic effects in combinations with isoniazid against M. tuberculosis [58]. In addition, some 
flavonoids have been found to possess powerful antimycobacterial effects when tested alone, such as 
isobachalcone (MIC 2.2 µg/mL against M tuberculosis) isolated from the West-African plant Dorstenia 
barteri (Moraceae) [59]. Thus, in depth efforts should be made to investigate the flavonoid 
components in Anogeissus spp. and to isolate these flavonoids in order to investigate their 
antimycobacterial effects alone and in combinations with other flavonoids and with conventional 
anti-TB drugs, such as rifampicin and isoniazid. 
Some structure–activity relations and mechanisms of action have been studied regarding the 
antimycobacterial effects of flavonoids. It has been found that the antimycobacterial potential of 
flavonoids is mainly dependent on the presence of a heterocyclic ring, the presence and position of 
functional groups (-OH, -OMe) and a carbon composition of C6-C3-C6 in their molecular structure 
[60]. Additionally, it has been found that the flavonoid structure is suitable for the development of 
M. tuberculosis proteasome inhibitors [61,62]. DNA-gyrase in M. tuberculosis is an important drug 
target, and taxifolin and quercetin are able to bind to this protein [52,63]. Moreover, flavonoids have 
lipid peroxidation activity and antioxidant activity, which could also affect their antimycobacterial 
potential [64]. Additionally, some flavonoids, such as butein and isoliquiritigenin have been found 
to inhibit fatty acid and mycolic acid synthesis and thus to affect the formation of the mycobacterial 
cell membrane and cell wall [3]. 
4. Materials and Methods  
4.1. Plant Material  
The plant material of Anogeissus leiocarpa was collected from a natural woodland forest in the 
Blue Nile region in southeastern Sudan (Figure 1). The plants were identified and authenticated at 
the Faculty of Forestry, University of Khartoum, Sudan, and voucher specimen and voucher numbers 
were deposited at the University of Khartoum, Sudan. The stem, leaves, fruits, and roots of the plant 
specimens were air-dried in the shade. Stems and roots were manually debarked to separate the stem 
bark from the wood and the root bark from the root. The dried plant parts were manually chipped to 
small pieces and ground using a grinder machine.  
4.2. Extraction  
4.2.1. Cold and Hot Methanol Extraction 
For the cold methanol extraction, 20 g of the plant material was added to 400 mL of methanol 
and stirred overnight in a magnetic stirrer (RCT basic digital). The resulting extracts were centrifuged 
at 2500 rpm for 10 min (Eppendorf AG centrifuge 5810 R, Germany), whereafter the supernatants 
were freeze-dried in a lyophilizer (HETO LyoPro 3000, Denmark) for three days.  
For the hot methanol extraction using the Soxhlet technique, 800 mL of methanol was added to 
20–100 g of powder from various plant parts. Extraction was performed for 5 hours. A rotary 
evaporator (Heidolph VV2000) was used to evaporate the solvent of the extracts, after which the 
extracts were freeze-dried for 1–2 days. 
The extracts obtained from these methods were dissolved in methanol (50 mg/mL) for 
antimycobacterial screening. Additionally, the methanolic Soxhlet extracts at 5 mg/mL (in MeOH: 
H2O, 1:1) were subjected to further UHPLC/QTOF-MS phytochemical analysis.  
4.2.2. Macerations and Hot Water Decoctions 
Cold and hot water extracts were prepared in accordance with African traditional medicinal 
knowledge. For the macerations, 500 mL of distilled water was added to 20 g of the plant powder 
and extracted for 24 h using a magnetic stirrer (RCT basic digital). For the decoctions, 500 mL of water 
were added to the plant powder and left to boil for 5 minutes.  
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Extracts obtained from both methods were transferred into Eppendorf centrifuge tubes (volume 
50 mL, Germany) and centrifuged at 3000 rpm (Eppendorf AG centrifuge 5810 R, Germany) for 15 
min. The resulting supernatants were collected and filtered using a vacuum pump filtration 
technique and Whatman filter paper (⌀ 150 mm, Germany). The filtered extracts were placed in −20° 
C for 24 hours, whereafter they were lyophilized to dryness for 1–3 days using a (HETO LyoPro 3000, 
Denmark) lyophilizer.  
4.2.3. Sequential Extraction and Solvent Partition  
In brief, sequential extraction was performed according to the method described by Salih et al. 
2017a and 2017b [18,65]. A total of 100 g of the plant materials of A. leiocarpa were subjected to a 
sequential extraction method using solvents with increasing polarities. First, the plant material was 
extracted with hexane (1000 mL), followed by dichloromethane or chloroform (1200 mL) and acetone 
(900 mL) in the case of the root and root bark. Following this sequential extraction, liquid–liquid 
fractionation was used. In this method, ethyl acetate was added to extracts that contained 80% 
methanol, and separation was performed in a separation funnel (a Nalgene® FEP). All extracts were 
dried in the rotary evaporator, whereafter they were freeze-dried in a lyophilizer. The obtained 
extracts were subjected to antimycobacterial testing. 
The percentage extraction yields for the extracts were calculated as the ratio of the extract dry 
weight to the dry weight of the plant material used for the extraction according to the below formula 
[66]:  
Percentage extraction yield (%) = (
weight of the dry extract
weight of dry plant material before extraction
) 100  
4.3. Phytochemical Analysis 
4.3.1. Thin Layer Chromatography and Antioxidant Analysis Using The DPPH-Reagent 
A root extract of A. leiocarpa, extracted using hot methanol Soxhlet extraction, was subjected to 
preparative and analytic reversed phase TLC and antioxidant analysis to isolate fractions enriched 
with ellagic acid derivatives and to detect the antioxidant compounds in these fractions. Reversed 
phase silica gel (RP18 F 254 s, Merck, Germany) plated glass plates (20 × 20 cm) were used for the 
separations, and aluminum backed plates with the same solid phase were used for analytical TLC. A 
volume of 10 µL of the standard compounds, ellagic acid, corilagin, and gallic acid (Sigma-Aldrich, 
1mg/mL) was applied on the thin layer plates. Additionally, 20–30 µl of extracts in methanol (50 
mg/mL) were applied in 5–10 µl volumes at a time (using a glass Pasteur pipette, P 4518-5X, 
Accupipette TM Pipets/ DADE and DURAN®, ring Caps, Germany) at the baseline of the thin layer 
plate and allowed to dry between the applications. Compound and pure compound applications 
were repeated 2–3 times. The eluent for the TLC separations consisted of 
methanol:water:orthophosphoric acid (50 mL:50 mL:1000 µL). The plates were developed until the 
solvent front reached 12.7 cm (application baseline at 1.5 cm). The dried plates were examined under 
a UV-detector (Camaq Reprostar 3 TLC Visualizer) to identify the fluorescent and quenching bands 
at 366 and 254 nm, respectively. The retardation factor (Rf) of the fractions was measured using the 
below formula as the relation of the distance moved by the fractions to the distance moved by the 
eluent front: 
Rf =
Distance moved by the fractions
Distance moved by the solvent
  
For the preparative thin-layer fractionation, the fractions were scraped from 15 plates, and bands 
showing the same Rf value were combined into the same glass tube. Methanol (2–5 mL) was added 
to the glass tubes with the fractions in order to extract the compound (-s) from the silica gel. After 
this extraction step, the glass tubes were centrifuged at 5000 rpm for 10 minutes (Mini Spin® plus, 
Eppendorf, Germany) and the supernatants were collected. In order to obtain the dry weights of the 
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obtained fractions, the methanol was evaporated using a heating centrifuge (Concentrator Plus, 
Eppendorf), whereafter the separated fractions were weighed and dissolved in methanol:water (1:1) 
for HPLC-DAD- and UHPLC/QTOF MS-analysis.  
The DPPH (2,2-diphenyl-1-picrylhydrazyl, C18H12N5O6, Sigma-Aldrich) reagent (0.2% w/v in 
methanol) was used for the qualitative evaluation of the oxidative reaction of the separated spots on 
the thin layer plates in visual light. The antioxidant compounds turned their color from violet to 
yellowish or colorless due to reactions and neutralization with the DPPH of the various functional 
groups in the detected compounds. The separated spots were compared with the standard 
compounds corilagin, ellagic acid, and gallic acid (Sigma-Aldrich).  
4.3.2. HPLC-UV/DAD Method 
Analysis was performed using the Agilent Chemstation HPLC-UV/DAD system (Waters Corp., 
Milford, USA) and employing the method described by Salih et al. 2017a [18] and Salih 2019 [9]. The 
HPLC was connected with a controller, a water pump (600 E), and a diode-array detector UV (a 991 
PDA). The separation was performed using an analytical Hypersil reversed phase C-18 column 
(length: 10 mm; ID: 2 mm). The eluents of the mobile phase consisted of solvent A, an aqueous 
solution that consisted of 1.5% tetrahydrofuran and 0.2% of orthophosphoric acid, and solvent B, 
which was 100% methanol. Gradient elution was used as described by Salih et al., 2017a [18], and the 
flow rate and injection volume were 2 mL/min and 10 µl (2 mg/mL in 50% MeOH), respectively. The 
wavelengths were set at 220, 270, 280, 320, and 360 nm, and the UVλ absorption maxima spectra of 
the identified compounds were recorded. The compounds were compared with a natural compounds 
library available in the computer Agilent Chemstation library. Moreover, the compounds were 
compared with data reported in literature [9,18,67,68]. 
4.3.3. UHPLC/Q-TOF MS Method  
The methods described by Taulavuori et al. 2013 [69], Fyhrquist et al., 2014a [34], and Salih et al. 
2017a [18] and Salih 2019 [9] were used to characterize the compounds of interest and to obtain the 
molecular ions in negative mode as [M-H]- values. The UHPLC/Q-TOF MS apparatus was equipped 
with UHPLC-DAD for the compound separations (Model 1200 Agilent Technologies)-
JETSTREAM/QTOFMS (Model 6340 Agilent Technologies) and a reversed phase column (2.1 × 60 
mm, 1.7 µm C18 column, Agilent technologies). The mobile phase included solvent A, 1.5% of 
tetrahydrofuran and 0.25% of acetic acid in ionized water, and solvent B was 100% methanol. The 
UHPLC-runs were made using the following gradient: from 0 to 1.5 min, 0% B; from 1.5 to 3 min, 0–
15% B; from 3 to 6 min, 10–30% B; from 6 to 12 min, 30–50% B; from 12 to 20 min, 50–100% B; and 
from 20 to 22 min, 100–0% B. All molecular ions were acquired in the negative ion mode with the 
mass range from 100 to 2000 m/z. The acquired ions were compared with the literature [67].   
4.4. Antimycobacterial Activity Tests 
4.4.1. Agar Diffusion Method 
The methods described by Fyhrquist et al. 2014 b [70] and Salih et al. 2018 [71] were used. 
Mycobacterium smegmatis ATCC 14468 was grown for five days at +37 °C on agar slants containing a 
Löwenstein–Jensen agar medium (Becton–Dickinson and Company, USA). For the test, petri dishes 
(Ø 14 cm, Bibby Sterilin, UK) that were filled with a base layer of 25 mL agar (Antibiotic medium 
Number 2, Difco, Molesey, UK) and 25 mL Middlebrook 7H10 agar (Difco) supplemented with oleic 
albumin dextrose catalase supplement (OADC, Difco) as a top layer were used. 200 µL of 
Mycobacterium suspension in sodium chloride (0.9% w/v) containing approximately 1.0 × 108 CFU/mL 
was aseptically applied to the petri dish. After this inoculation, filter paper disks (Ø 12.7 mm, 
Schleicher and Schuell) loaded with 200 µL of the extracts (50 mg/mL) and the positive control, 
rifampicin (10 mg/mL, Sigma-Aldrich) were aseptically and equidistantly placed on the petri dishes. 
Then, 200 µL of the solvents that were used to dissolve the plant extracts, methanol and hexane, were 
used as negative controls. Prior to incubation, all petri dishes containing extracts and positive and 
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negative controls were left in the cold room (+4 °C) for two hours. Incubation was at +37 °C for five 
days. Experiments were performed in triplicates and the diameters of the IZD were measured in 
millimeters. The results were expressed as the mean IZD of the triplicates ± standard error of means 
(SEM). Moreover, the activity index (AI) of the various extracts was evaluated as the relation of the 
IZD of the extracts compared to the IZD of rifampicin, as shown in the equation below [70].  
AI (Activity Index) =  
Inhibition zone of the plant extract
Inhibition zone of rifampicin
  
Agar diffusion was used for the measurement of approximate MIC values for some of the 
extracts due to the excess turbidity resulting from precipitation of the compounds in these extracts 
(such as some methanol and hexane extracts). Thus, the MIC values for these extracts could not be 
measured with the microplate method. In brief, for these experiments, 200 µL of two-fold dilutions 
of the extracts were prepared (5 mg/mL–39 µg/mL dilutions) and pipetted on filter papers to 
determine the MIC value for these extracts. The lowest concentration that showed a small but still 
visible inhibition zone (≤1 mm) was considered as the minimum inhibitory concentration.  
4.4.2. Turbidimetric Microplate Method 
Using the methods described in Fyhrquist et al. 2014 b [70] and Salih et al. 2018 [71], extracts, 
pure compounds, positive and negative controls, and fractions obtained from the thin layer 
chromatography were subjected to a turbidimetric microplate test to obtain the minimum inhibitory 
concentration. Two-fold dilutions of the plant extracts were made in methanol from 5 to 39 µg/mL. 
The preparative TLC fractions (Fr 3, 4, 6, and 8) from a methanolic root extract of A. leiocarpa were 
diluted in methanol to achieve concentrations of 1500, 1000, 2000, and 3000 µg/mL, respectively, and 
two-fold dilutions were made from these stock solutions until 3.91 µg/mL was reached. Rifampicin 
was diluted from 1000 to 1.953 µg/mL). The standard compounds, gallic acid (G-7384, Sigma-Aldrich, 
Dermstadt, Germany), ellagic acid (Sigma-Aldrich), corilagin (Sigma-Aldrich), quercetin (Merk Art. 
7546, Darmstadt, Germany), and apigenin (Etrasynthese 69730 Genay, France) were used as reference 
compounds that are known to occur in A. leiocarpa. These reference compounds were prepared as 
two-fold dilutions from 1000 to 0.030 µg/mL. 
Before the microplate test, a few colonies of Mycobacterium smegmatis ATCC 14468 were 
transferred to 15 mL of the Dubos broth (Difco) and incubated for three days at +37 °C and 200 rpm. 
For the test, 2 mL of the suspension were pipetted into a glass tube; 1 mL was then pipetted into a 
disposable UV Cuvette (BrandTech®, Essex, NJ, USA) to measure the turbidity at 625 nm using a UV–
visible spectrophotometer (Pharmacia LKB-Biochrom 4060). The remaining suspension in the glass 
tube was then diluted to reach an absorbance of 0.1 (containing approximately 1 × 108 CFU/ mL). This 
suspension was diluted further according to the guidelines of the Clinical and Laboratory Standards 
Institute 2013 [72], who recommend an inoculum of 2.5 × 105 CFU/mL for Mycobacterium smegmatis 
MIC testing. A volume of 100 µl of suspension containing 5 × 105 CFU/mL was added to the 96-well 
microplate wells (Nunc, Nunclon, Roskilde, Denmark) containing 100 µL of extracts, TLC fractions, 
pure compounds, or rifampicin, thus resulting in a final inoculum of 2.5 × 105 CFU/mL. A total of 100 
µL of the growth control (bacterial suspension containing 5 × 105 CFU/mL) and 100 µL of broth were 
added to the growth control wells to reach the same CFU/mL as in the test wells (a final inoculum of 
2.5 × 105 CFU/mL). Moreover, solvent controls (methanol and hexane) were added to the wells in the 
same maximum percentages as in the wells containing the highest concentrations of extracts (that 
meant a maximum volume percentage of 5% for the solvents). The solvents (at max. 5% volume of 
the suspension) were found to not be toxic to M. smegmatis. The microplates were incubated at +37 ˚C 
for four days, whereafter the turbidity of the wells was measured at 620 nm using a Victor 1420 
(Wallac, Turku, Finland) spectrophotometer. 
All assays were done in triplicate, and as shown in the equation below, the results are expressed 
as the mean percentage of growth inhibition of triplicates compared to the growth of the growth 
control ( = 100% growth). Sample controls (SC, containing only plant extract and broth, without 
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bacterium) were used to subtract the turbidity resulting from the plant extracts (the turbidity of test 
well with plant extract and bacterium minus turbidity of sample control containing the same plant 
extract but no bacteria). The smallest concentration that inhibited ≥90% of the mycobacterial growth 
was considered as the MIC value [71]. 
Formula (1 and 2) used for the calculation of growth inhibition: 
% bacterial growth =  ቈ
(xതGT A620 – xതSC A620)
xതGC A620
  100቉ (1) 
% inhibition of growth = 100 (% growth of the growth control) – ቂ(୶തୋ୘ ୅଺ଶ଴ – ୶തୗେ ୅଺ଶ଴)
୶തୋେ ୅଺ଶ଴
  100ቃ (2) 
where GT A620 is the turbidity of the test well at 620 nm (containing plant samples, pure compounds 
or antibiotics and microbial cells), SC A620 is the sample control (consisting of the plant samples, the 
compounds or antibiotics alone, without microbial cells), and GC A620 is the turbidity of the growth 
control at 620 nm (containing only bacterial cells). x̅ is the average of the triplicates.  
In addition, the total activity of a plant extract was calculated as the mass extracted from the 
plant material (in mg/1000 mg starting material) divided by the MIC (in mg/mL) value of this extract. 
5. Conclusions 
The results from this investigation indicated that extracts of the African medicinal plant 
Anogeissus leiocarpa contains compounds that might have use for the treatment of tuberculosis. Our 
results could justify the traditional oral application of utilizing water extracts and decoctions of A. 
leiocarpa roots, leaves, and stem bark to treat cough related to TB. Moreover, our results indicate that 
ethanol extracts could be preferred for traditional use, since alcohol extracts more compounds than 
water.  
To the best of our knowledge, this is the first time extracts and fractions of A. leiocarpa have been 
tested for their antimycobacterial effects against M. smegmatis. Our RP18-TLC fractionation of A. 
leiocarpa roots resulted in the separation of some ellagic acid enriched fractions that were more active 
than the crude methanol extract. Of the active compounds in these fractions, di-methyl ellagic acid 
and di-methyl ellagic acid xyloside were enriched in some of the fractions, and these compounds 
have been found to possess promising antimycobacterial effects. Thus, A. leiocarpa could be a good 
source for these antimycobacterial ellagic acid derivatives.  
Ellagic acid-based glycosides are difficult to synthesize due to the O-glycosylation step, and thus 
the possibility to use plants (and their renewable organs such as leaves) as sources for EA glycosides 
should be investigated.  
Our results indicate that in addition to its ellagic acid derivatives, A. leiocarpa contains a high 
variety of compounds with potential antimycobacterial activity such as flavonoids (especially 
taxifolin) and stilbenes (pinosylvin and 4′-methylpinosylvin). Moreover, a number of ellagitannins 
have been characterized in A. leiocarpa that could have good antimycobacterial effects in vivo via their 
metabolically available urolithins. 
Further in-depth studies should be performed on fractions and compounds isolated from A. 
leiocarpa, to investigate their individual effects on various strains on M. tuberculosis, as well to study 
the antimycobacterial potential of extracts and isolated fractions/compounds in combinations with 
conventional anti-TB drugs, such as rifampicin and isoniazid.  
Author Contributions: E.Y.A.S. performed the data collections, extractions, fractionation, and antimycobacterial 
analysis. E.Y.A.S. and P.J.F. performed preliminary screening for the chemical constituents of extracts and 
fractions using HPLC DAD, in addition to analyzing the UV absorption spectra for the studies peaks. R.J.-T., 
provided pivotal support in analytical chemistry using UHPLC/Q-TOFMS. P.J.F. designed and managed the 
antimycobacterial test. E.Y.A.S. planned and performed the practical antimycobacterial tests. E.Y.A.S. wrote the 
manuscript together with P.J.F. and M.K.M.F. provided constructive criticism and edition to the manuscript. 
O.L. and M.S. have thoroughly revised and edited the manuscript and approved the final version of this paper. 
Antibiotics 2020, 9, 364 25 of 28 
Funding: This research was funded by Ekhaga Foundation, project grant 2017-7 (Stockholm, Sweden) and the 
Ministry of Higher Education and University of Khartoum, Sudan. 
Acknowledgment: The first author would like to thank the Ministry of Higher Education and University of 
Khartoum, Sudan for providing the initial financial support to conduct this research. The financial support 
provided by Ekhaga Foundation (Stockholm, Sweden) is greatly acknowledged by the first and the last author.  
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the 
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to 
publish the results. 
References 
1. World Health Organization (WHO). Global Tuberculosis Report; App Launched; World Health Organization 
(WHO): Geneva, Switzerland, 2020. Available online: https://www.who.int/tb/en/ (accessed on 20 February 
2020). 
2. American Lung Association. Learn About Tuberculosis. 2018. Available online: 
https://www.lung.org/lung-health-and-diseases/lung-disease-lookup/tuberculosis/learn-about-
tuberculosis.html (accessed on 25 December 2019). 
3. Askun, T. The significance of Flavonoids as Potential Anti-Tuberculosis compounds. RRJPTS 2015, 6–17. 
4. World Health Organization (WHO). Global Tuberculosis Report; World Health Organization (WHO): 
Geneva, Switzerland, 2013. Available online https://apps.who.int/iris/handle/10665/91355 (accessed on 23 
December 2019). 
5. World Health Organization (WHO). Global Tuberculosis Report; World Health Organization (WHO): 
Geneva, Switzerland, 2018. ISBN 978-92-4-156564-6. Available online: 
https://www.who.int/tb/publications/global_report/gtbr2018_main_text_28Feb2019.pdf?ua=1 (accessed on 
25 December 2019). 
6. World Health Organization (WHO). Global Tuberculosis Report; World Health Organization (WHO): 
Geneva, Switzerland, 2019. Available online: https://www.who.int/tb/publications/factsheet_global.pdf 
(accessed on 25 February 2020). 
7. Asres, A.; Jerene, D.; Deressa, W. Delays to anti-tuberculosis treatment initiation among cases on directly 
observed treatment short course in districts of southwestern Ethiopia: A cross sectional study. BMC Infect. 
Dis. 2019, 19, 481. 
8. The World Bank. Tuberculosis. Available online: 
https://www.worldbank.org/en/topic/health/brief/tuberculosis-control (accessed on 16 June 2019). 
9. Salih, E.Y.A. Ethnobotany, Phytochemistry and Antimicrobial Activity of Combretum, Terminalia and 
Anogeissus Species (Combretaceae) Growing Naturally in Sudan. Ph.D. Thesis, University of Helsinki, 
Helsinki, Finland, 2019; pp. 1–193. 
10. Masoko, P.; Nxumalo, K.M. Validation of antimycobacterial plants used by traditional healers in three 
districts of the Limpopo province (South Africa). Evid. Based Complementary Altern. Med. 2013, 586247. 
11. York, T.; Van Vuuren, S.F.; De Wet, H. An antimicrobial evaluation of plants used for the treatment of 
respiratory infections in rural Maputaland, KwaZulu-Natal, South Africa. J. Ethnopharmacol. 2012, 144, 118–
127. 
12. Luo, X.; Pires, D.; Aínsa, J.A.; Gracia, B.; Mulhovo, S.; Duarte, A.; Anes, E.; Ferreira, M.J.U. 
Antimycobacterial evaluation and preliminary phytochemical investigation of selected medicinal plants 
traditionally used in Mozambique. J. Ethnopharmacol. 2011, 137, 114–120. 
13. The Plant List Database 2010. A Working List for All Plant Species. Available online: 
http://www.theplantlist.org/ (accessed on 25 March 2019). 
14. Bello, A.A.; Jimoh, A.A. Some physical and mechanical properties of African birch (Anogeissus leiocarpus) 
timber. J. Appl. Sci. Environ. Manag. 2018, 22, 79–84. 
15. Hennenberg, K.J.; Goetze, D.; Minden, V.; Traoré, D.; Porembski, S. Size-class distribution of Anogeissus 
leiocarpus (Combretaceae) along forest–savanna ecotones in northern Ivory Coast. J. Trop. Ecol. 2005, 21, 
273–281. 
16. Arbab, A.H. Review on Anogeissus leiocarpus a potent African traditional drug. Int. J. Res. Pharm. Chem. 2014, 
4, 496–500. 
Antibiotics 2020, 9, 364 26 of 28 
17. El Ghazali, G.E.B.; Abdalla, W.E.; Khalidm, H.E.; Khalafalla, M.M.; Hamad, A.A. Medicinal Plants of the 
Sudan, part V. In Medicinal Plants of Ingassana Area. Sudan; National Centre for Research, Sudan Currency 
Printing Press: Khartoum, Sudan, 2003. 
18. Salih, E.Y.A.; Kanninen, M.; Sipi, M.; Luukkanen, O.; Hiltunen, R.; Vuorela, H.; Julkunen-Tiitto, R.; 
Fyhrquist, P. Tannins, flavonoids and stilbenes in extracts of African savanna woodland trees Terminalia 
brownii, Terminalia laxiflora and Anogeissus leiocarpus showing promising antibacterial potential. S. Afr. J. 
Bot. 2017, 108, 370–386. 
19. Victor, Y.A. In-Vitro Assessment of Antioxidant and Antimicrobial Activities of Methanol Extracts of Six 
Wound Healing Medicinal Plants. J. Nat. Sci. Res. 2013, 3, 74–82. 
20. Mann, A.; Amupitan, J.O.; Oyewale, A.O.; Okogun, J.I.; Ibrahim, K.; Oladosu, P.; Lawson, L.; Olajide, I.; 
Nnamdi, A. Evaluation of in vitro antimycobacterial activity of Nigerian plants used for treatment of 
respiratory diseases. Afr. J. Biotechnol. 2008, 7, doi:10.5897/AJB08.438.  
21. Elegami, A.A.; El-Nima, E.I.; Tohami, M.E.; Muddathir, A.K. Antimicrobial activity of some species of the 
family Combretaceae. Phytother. Res. 2002, 16, 555–561. 
22. Gberikon, G.M.; Agada, J.O.; Yaji, M.E. Synergistic Effects of Anogeissus leiocarpus and Morinda lucida 
Leaves, Stems and Roots Extracts against Some Enteric Bacteria. IJSRP 2019, 9, 851–860. 
23. Garbi, M.I., Kabbashi, A.S., AbdelhafizElshikh, A. Bacteriostatic Effect of Anogeissus leicarpus Methanolic 
Leaves Extract. Res. Adv. Pharm. Life Sci. 2019, 2, doi:10.5281/zenodo.3548251. 
24. Mann, A.; Yusuf, A.; Daniyan, S. TLC analysis and bioactivity screening of the stem bark extract of 
Anogeissus leiocarpus against multi-resistant Staphylococcus aureus and quantification of its 
phytoconstituents. Res. J. Pharm. Biol. Chem. Sci. 2014, 5, 187–203. 
25. Muraina, I.A.; Adaudi, A.O.; Mamman, M.; Kazeem, H.M.; Picard, J.; McGaw, L.J.; Eloff, J.N. 
Antimycoplasmal activity of some plant species from northern Nigeria compared to the currently used 
therapeutic agent. Pharm. Biol. 2010, 48, 1103–1107. 
26. Orlando, G.; Ferrante, C.; Zengin, G.; Sinan, K.I.; Bene, K.; Diuzheva, A.; Jekő, J.; Cziáky, Z.; Di Simone, S.; 
Recinella, L.; et al. Qualitative Chemical Characterization and Multidirectional Biological Investigation of 
Leaves and Bark Extracts of Anogeissus leiocarpus (DC.) Guill. & Perr. (Combretaceae). Antioxidants 2019, 8, 
343. 
27. Eltayeb, I.M.; Muddathir, A.K.; Ali, H.A.R.; Ayoub, S.M.H. A comparative Study of In vitro Susceptibility 
of Madurella mycetomatis to Anogeissus leiocarpous Leaves, Roots and Stem Barks Extracts. Am. J. Phytomed. 
Clin. Ther. 2016, 4, 135–164. 
28. Ndjonka, D.; Abladam, E.D.; Djafsia, B.; Ajonina-Ekoti, I.; Achukwi, M.D.; Liebau, E. Anthelmintic activity 
of phenolic acids from the axlewood tree Anogeissus leiocarpus on the filarial nematode Onchocerca ochengi 
and drug-resistant strains of the free-living nematode Caenorhabditis elegans. J. Helminthol. 2014, 88, 481–488. 
29. Hubert, J.J.-M.N.; Sylvain, P.; Mahmoud, H.; Nicolas, B.; Romain, R.; Jean-Hugues, R. Identification of 
natural metabolites in mixture: A pattern recognition strategy based on 13C NMR. Anal. Chem. 2014, 86, 
2955–2962. 
30. Hamzaoui, M.; Renault, J.H.; Reynaud, R.; Hubert, J. Centrifugal partition extraction in the pH-zone-
refining displacement mode: An efficient strategy for the screening and isolation of biologically active 
phenolic compounds. J. Chromatogr. B 2013, 937, 7–12. 
31. Shuaibu, M.N.; Pandey, K.; Wuyep, P.A.; Yanagi, T.; Hirayama, K.; Ichinose, A.; Tanaka, T.; Kouno, I. 
Castalagin from Anogeissus leiocarpus mediates the killing of Leishmania in vitro. Parasitol. Res. 2008, 103, 
1333–1338. 
32. Attioua, B.; Lagnikab, L.; Yeoc, D.; Antheaumed, C.; Kaisere, M.; Wenigerf, B.; Vonthron-Sénécheauf, C. In 
vitro antiplasmodial and antileishmanial activities of flavonoids from Anogeissus leiocarpus (Combretaceae). 
Int. J. Pharmaceut. Rev. Res. 2011, 11, 1–6. 
33. Salih, E.; Julkunen-Tiitto, R.; Kanninen, M.; Sipi, M.; Luukkanen, O.; Vuorela, H.; Fyhrquist, P. 
Characterization of antibacterial flavonoids and stilbenes of the root extract of Anogeissus leiocarpus by 
UHPLC-MS-QTOF. Planta Med. 2015, 81, PM_77. 
34. Fyhrquist, P.; Salih, E.; Hiltunen, R.; Vuorela, H.; Julkunen-Tiitto, R. Ellagitannins, ellagic acid derivatives 
and ampelopsin in antimicrobial root and stem bark extracts of some selected African species of Terminalia 
and Anogeissus leiocarpus. Planta Med. 2014, 80, P1L10, doi:10.1055/s-0034-1394668. 
35. Tyagi, J.S.; Sharma, D. Mycobacterium smegmatis and tuberculosis. Trends Microbiol. 2002, 2, 68–69. 
Antibiotics 2020, 9, 364 27 of 28 
36. Panas, M.W.; Jain, P.; Yang, H.; Mitra, S.; Biswas, D.; Wattam, A.R.; Jacobs, W.R. Noncanonical SMC protein 
in Mycobacterium smegmatis restricts maintenance of Mycobacterium fortuitum plasmids. Proc. Natl. Acad. Sci. 
USA 2014, 111, 13264–13271. 
37. Eloff, J.N. A proposal on expressing the antibacterial activity of plant extracts - a small first step in applying 
scientific knowledge to rural primary health care in South Africa. S. Afr. J. Sci. 2000, 96, 116–118. 
38. Heftmann, E. Chromatography: Fundamentals and Applications of Chromatographic and Electrophoretic Methods. 
Part A: Fundamentals and Techniques; Elsevier Scientific Publishing Company: Amsterdam, The Netherlands, 
2011; pp. 423–425. 
39. Kuete, V.; Tabopda, T.K.; Ngameni, B.; Nana, F.; Tshikalange, T.E.; Ngadjui, B.T. 2010. Antimycobacterial, 
antibacterial and antifungal activities of Terminalia superba (Combretaceae). S. Afr. J. Bot. 2010, 76, 125–131. 
40. Patil, U.H.; Gaikwad, D.K. Ethno-pharmacological review of a herbal drug: Anogeissus latifolia. Int. J. 
Pharma. Sci. Res. 2011, 2, 41–43. 
41. Kaneko, E.; Kaneko, M. Sugar Derivatives and Application of Same. U.S. Patent 8,350,024 B2, 8 January 
2013. 
42. Adigun, J.O.; Amupitan, J.O.; Kelly, D.R. Isolation and investigation of antimicrobial effect of 3, 4, 3'-tri-O-
methylflavellagic acid and its glucoside from Anogeissus leocarpus. Bull. Chem. Soc. Ethiop. 2000, 14, 169–174. 
43. Kondo, Y.; Toida, T.; Kusano, G.; Imai, J. Specific inhibition of formation of acid-fastness in mycobacteria 
by 3, 3′-di-O-methylellagic acid. Experientia 1979, 35, 599–600. 
44. Shilpi, J.A.; Ali, M.T.; Saha, S.; Hasan, S.; Gray, A.I.; Seidel, V. Molecular docking studies on InhA, MabA 
and PanK enzymes from Mycobacterium tuberculosis of ellagic acid derivatives from Ludwigia adscendens and 
Trewia nudiflora. Silico Pharmacol. 2015, 3, 10. 
45. Asres, K.; Bucar, F.; Edelsbrunner, S.; Kartnig, T.; Höger, G.; Thiel, W. Investigations on antimycobacterial 
activity of some Ethiopian medicinal plants. Phytother. Res. 2001, 15, 323–326. 
46. Diop, E.A.; Jacquat, J.; Drouin, N.; Queiroz, E.F.; Wolfender, J.L.; Diop, T.; Rudaz, S. Quantitative CE 
analysis of punicalagin in Combretum aculeatum extracts traditionally used in Senegal for the treatment of 
tuberculosis. Electrophoresis 2019, 40, 2820–2827. 
47. Espin, J.C.; Larrosa, M.; Garcia-Conesa, M.T.; Tomas-Barberan, F. Biological significance of urolithins, the 
gut microbial ellagic Acid-derived metabolites: The evidence so far. Evid. Based Complement. Alternat. Med. 
2013, 1–15. 
48. Villalba, K.J.O.; Barka, F.V.; Pasos, C.V.; Rodríguez, P.E. Food Ellagitannins: Structure, Metabolomic Fate, 
and Biological Properties. In Tannins-Structural Properties, Biological Properties and Current Knowledge; 
IntechOpen, London, UK, 2019. 
49. phane Quideau, S. Chemistry and Biology of Ellagitannins: An Underestimated Class of Bioactive Plant 
Polyphenols; World Scientific: Singapore, 2009. 
50. Puupponen-Pimiä, R.; Liisa, N.; Hanna-Leena, A.; Kirsi-Marja, O-C. The action of berry phenolics against 
human intestinal pathogens. Biofactors 2005, 23, 243–251. 
51. Mohan, C.G. Structural Bioinformatics: Applications in Preclinical Drug Discovery Process; Springer: 
Berlin/Heidelberg, Germany, 2019; Volume 27. 
52. Davis, C.K.; Nasla, K.; Anjana, A.K.; Rajanikant, G.K. Taxifolin as dual inhibitor of Mtb DNA gyrase and 
isoleucyl-tRNA synthetase: In silico molecular docking, dynamics simulation and in vitro assays. Silico 
Pharmacol. 2018, 6, 8. 
53. Jnawali, H.N.; Jeon, D.; Jeong, M.C.; Lee, E.; Jin, B.; Ryoo, S.; Kim, Y. Antituberculosis activity of a naturally 
occurring flavonoid, isorhamnetin. J. Nat. Prod. 2016, 79, 961–969. 
54. Safwat, N.A.; Kashef, M.T.; Aziz, R.K.; Amer, K.F.; Ramadan, M.A. Quercetin 3-O-glucoside recovered from 
the wild Egyptian Sahara plant, Euphorbia paralias L., inhibits glutamine synthetase and has 
antimycobacterial activity. Tuberculosis 2018, 108, 106–113. 
55. Sasikumar, K.; Ghosh, A.R.; Dusthackeer, A. Antimycobacterial potentials of quercetin and rutin against 
Mycobacterium tuberculosis H37Rv. 3 Biotech 2018, 8, 427. 
56. Suksamrarn, A.; Chotipong, A.; Suavansri, T.; Boongird, S.; Timsuksai, P.; Vimuttipong, S.; Chuaynugul, 
A. Antimycobacterial activity and cytotoxicity of flavonoids from the flowers of Chromolaena odorata. Arch. 
Pharm. Res. 2004, 27, 507–511. 
57. Boligon, A.A.; Agertt, V.; Janovik, V.; Cruz, R.C.; Campos, M.; Guillaume, D.; dos Santos, A.R. 
Antimycobacterial activity of the fractions and compounds from Scutia buxifolia. Rev. Bras. Farmacogn. 2012, 
22, 45–52. 
Antibiotics 2020, 9, 364 28 of 28 
58. Mativandlela, S.P.; Muthivhi, T.; Kikuchi, H.; Oshima, Y.; Hamilton, C.; Hussein, A.A.; Lall, N. 
Antimycobacterial flavonoids from the leaf extract of Galenia africana. J. Nat. Prod. 2009, 72, 2169–2171. 
59. Kuete, V.; Ngameni, B.; Mbaveng, A.T.; Ngadjui, B.; Meyer, J.M.; Lall, N. Evaluation of flavonoids from 
Dorstenia barteri for their antimycobacterial, antigonorrheal and anti-reverse transcriptase activities. Acta 
Trop. 2010, 116, 100–104. 
60. Xie, Y.; Yang, W.; Tang, F.; Chen, X.; Ren, L. Antibacterial activities of flavonoids: Structure-activity 
relationship and mechanism. Curr. Med. Chem. 2015, 22, 132–149. 
61. Zheng, Y.; Jiang, X.; Gao, F.; Song, J.; Sun, J.; Wang, L.; Sun, X.; Lu, Z.; Zhang, H. Identification of plant-
derived natural products as potential inhibitors of the Mycobacterium tuberculosis proteasome. BMC 
Complement. Altern. Med. 2014, 14, 400. 
62. Pawar, A.; Jha, P.; Chopra, M.; Chaudhry, U.; Saluja, D. Screening of natural compounds that targets 
glutamate racemase of Mycobacterium tuberculosis reveals the anti-tubercular potential of flavonoids. Sci. 
Rep. 2020, 10, 949. 
63. Mdluli, K.; Ma, Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect. Disord. 
Drug Targets Former. Curr. Drug Targets Infect. Disord. 2007, 7, 159–168. 
64. Kumar, S.; Pandey, A.K. Chemistry and biological activities of flavonoids: An overview. Sci. World J. 2013, 
doi:10.1155/2013/162750. 
65. Salih, E.Y.; Fyhrquist, P.; Abdalla, A.; Abdelgadir, A.Y.; Kanninen, M.; Sipi, M.; Luukkanen, O.; Fahmi, 
M.K.; Elamin, M.H.; Ali, H.A. LC-MS/MS tandem mass spectrometry for analysis of phenolic compounds 
and pentacyclic triterpenes in antifungal extracts of Terminalia brownii (Fresen). J. Antibiot. 2017, 6, 37. 
66. Honarvar, B.; Sajadian, S.A.; Khorram, M.; Samimi, A. Mathematical modeling of supercritical fluid 
extraction of oil from canola and sesame seeds. Braz. J. Chem. Eng. 2013, 30, 159–166. 
67. Pfundstein, B.; El Desouky, S.K.; Hull, W.E.; Haubner, R.; Erben, G.; Owen, R.W. Polyphenolic compounds 
in the fruits of Egyptian medicinal plants (Terminalia bellerica, Terminalia chebula and Terminalia horrida): 
Characterization, quantitation and determination of antioxidant capacities. Phytochemistry 2010, 71, 1132–
1148. 
68. Conrad, J.; Vogler, B.; Reeb, S.; Klaiber, I.; Papajewski, S.; Roos, G.; Vasquez, E.; Setzer, M.C.; Kraus, W. 
Isoterchebulin and 4, 6-O-Isoterchebuloyl-D-glucose, Novel Hydrolyzable Tannins from Terminalia 
macroptera. J. Nat. Prod. 2001, 64, 294–299. 
69. Taulavuori, K.; Julkunen-Tiitto, R.; Hyöky, V.; Taulavuori, E. Blue mood for superfood. J. Nat. Prod. 
Commun. 2013, 8, 1–2. 
70. Fyhrquist, P.; Laakso, I.; Marco, S.G.; Julkunen-Tiitto, R.; Hiltunen, R. Antimycobacterial activity of 
ellagitannin and ellagic acid derivate rich crude extracts and fractions of five selected species of Terminalia 
used for treatment of infectious diseases in African traditional medicine. S. Afr. J. Bot. 2014, 90, 1–16. 
71. Salih, E.Y.; Julkunen-Tiitto, R.; Lampi, A.M.; Kanninen, M.; Luukkanen, O.; Sipi, M.; Lehtonen, M.; Vuorela, 
H.; Fyhrquist, P. Terminalia laxiflora and Terminalia brownii contain a broad spectrum of antimycobacterial 
compounds including ellagitannins, ellagic acid derivatives, triterpenes, fatty acids and fatty alcohols. J. 
Ethnopharmacol. 2018, 227, 82–96. 
72. Matthew, A.W.; Franklin, R.C.; William, A.C.; Micheal, N.D.; George, M.E.; Janet, F.H.; Fred, C.T. Clinical 
Laboratory Standards Institute. Method for dilution antimicrobial susceptibility tests for bacteria that grow 
aerobically. In CLSI document M7-A7, 7th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 
2013; pp. 14–34. 
 
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
